Register for our free email digests:
Supernus Pharmaceuticals, Inc.
https://www.supernus.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Supernus Pharmaceuticals, Inc.
12 Approvals To Look Out For In Q4
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.
Keeping Track: Terlipressin Falls Short Of US FDA Approval; Novel NDAs From Pfizer And Apellis; New BTDs For Sanofi, BeyondSpring
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Stacked User Fee Calendar Puts Another Record-Setting Year For US FDA Novel Approvals Within Reach
With goal dates for almost 40 novel drugs and biologics coming up in the second half of 2020 after a record number of first half approvals, even the pandemic looks unlikely to prevent another solid year for innovative drugs at US FDA.
Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Biscayne Neurotherapeutics, Inc.
- Biscayne Neurotherapeutics Australia Pty, Ltd
- Shire plc
- Shire Laboratories Inc